Skip to main content
Clinical Trials/NCT05634148
NCT05634148
Completed
Phase 3

Effect of a Single Dose Infusion of Dexmedetomidine in Reducing Incidence of Emergence Agitation After Nasal Surgery - a Randomised Contolled Trial

Security Forces Hospital1 site in 1 country42 target enrollmentDecember 22, 2022

Overview

Phase
Phase 3
Intervention
Dexmedetomidine
Conditions
Postoperative Delirium
Sponsor
Security Forces Hospital
Enrollment
42
Locations
1
Primary Endpoint
Riker sedation-agitation score
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

Various pharmacological interventions have been attempted previously to prevent postoperative EA with variable results. These include use of opioids, propofol, midazolam, ketamine, magnesium and alpha-2 agonists like clonidine and dexmedetomidine. Dexmedetomidine have been used with different dosages and different timings of administration with variable results and at the expense of major hemodynamic disturbances. The objective of this study was to investigate the role of single dose of dexmedetomidine (0.5 mcg/kg) administered as 30 minutes infusion prior to extubation in reducing the incidence and severity of EA and coughing on extubation.

Detailed Description

Emergence agitation (EA) or delirium is a post anesthesia complication which is manifested as confusion, agitation, disorientation and aggressive behavior. It can lead to serious consequences including hemorrhage, removal of lines, drains and catheters, self-extubation and even falling out of bed resulting in severe injuries. EA is associated with cognitive deficit, physical dependence, increased hospital stay and higher mortality. There is wide variation in the incidence of EA in scientific literature ranging from 5 % to 27.3 %. There are no clear diagnostic criteria for EA because of its varied clinical manifestations. Although many risk factors have been identified including pain, presence of stress at the time of induction, induction with etomidate, use of premedication with benzodiazepines, hypoxemia, type of surgery, awakening in hostile and noisy environment and presence of urinary catheter. Patients undergoing nasal surgeries are in particular, at higher risk for EA due to a sense of suffocation secondary to nasal packing. Various pharmacological interventions have been attempted previously to prevent postoperative EA with variable results. These include use of opioids, propofol, midazolam, ketamine, magnesium and alpha-2 agonists like clonidine and dexmedetomidine. Dexmedetomidine have been used with different dosages and different timings of administration with variable results and at the expense of major hemodynamic disturbances. The objective of this study was to investigate the role of single dose of dexmedetomidine (0.5 mcg/kg) administered as 30 minutes infusion prior to extubation in reducing the incidence and severity of EA and coughing on extubation.

Registry
clinicaltrials.gov
Start Date
December 22, 2022
End Date
April 1, 2023
Last Updated
3 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Anwar ul Huda

Principle Investigator

Security Forces Hospital

Eligibility Criteria

Inclusion Criteria

  • We will include patients aged 15 years to 65 years, ASA 1-3 who are planned to undergo general anesthesia for elective nasal surgeries in which nasal packing is used postoperatively

Exclusion Criteria

  • We will exclude patients with known allergy to study medications, BMI more than 35, history of obstructive sleep apnea, history of psychiatric illness, pregnancy and presence of liver and renal diseases.

Arms & Interventions

Dexmedetomidine group

Patients in this group will receive intravenous dexmedetomidine before extubation

Intervention: Dexmedetomidine

Control group

Patients in this group will receive intravenous placebo (0.9 % saline) before extubation

Intervention: Dexmedetomidine

Outcomes

Primary Outcomes

Riker sedation-agitation score

Time Frame: 60 minutes

Assessment of emergence delirium after extubation. It has numbers from 1-7.

Secondary Outcomes

  • Postoperative pain score(60 minutes)
  • Opioid consumption(60 minutes)
  • Duration of stay in PACU(60 minutes)
  • Adverse events(60 minutes)

Study Sites (1)

Loading locations...

Similar Trials